Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  TEL AVIV STOCK EXCHANGE  >  Compugen Ltd.       IL0010852080

COMPUGEN LTD.

  Report  
End-of-day quote. End-of-day quote TEL AVIV STOCK EXCHANGE - 03/28
1547 ILa   +10.90%
06/03COMPUGEN : Presents Update on COM701 Phase 1 Trial at the 2019 ASCO Annual Meeting
PR
05/22COMPUGEN : to Present at the Jefferies 2019 Healthcare Conference
PR
05/20COMPUGEN : 1Q Earnings Snapshot
AQ
 SummaryChartsNewsRatingsCalendarCompanyFinancialsRevisions 
Financials (ILS)
Sales 2019 -
EBIT 2019 -127 M
Net income 2019 -125 M
Debt 2019 -
Yield 2019 -
Sales 2020 -
EBIT 2020 -110 M
Net income 2020 -112 M
Debt 2020 -
Yield 2020 -
P/E ratio 2019 -
P/E ratio 2020
Capi. / Sales2019 0
Capi. / Sales2020 0
Capitalization 686 M
More Financials
Company
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of... 
More about the company
Surperformance© ratings of Compugen Ltd.
Trading Rating : - Investor Rating :
More Ratings
Latest news on COMPUGEN LTD.
06/03COMPUGEN : Presents Update on COM701 Phase 1 Trial at the 2019 ASCO Annual Meeti..
PR
05/22COMPUGEN : to Present at the Jefferies 2019 Healthcare Conference
PR
05/21BRISTOL MYERS SQUIBB : Compugen Doses First Patient in COM701/Opdivo (Nivolumab)..
AQ
05/20COMPUGEN : 1Q Earnings Snapshot
AQ
05/20COMPUGEN : Doses First Patient in COM701/Opdivo® (Nivolumab) Combination Arm of ..
PR
04/04COMPUGEN : Palladio Biosciences Announces Appointment of Sanford Zweifach as Cha..
AQ
03/26COMPUGEN : Announces Purchase of Company Shares by its Board of Directors and Me..
PR
03/12COMPUGEN : Announces Issuance of Two U.S. Composition of Matter Patents for COM7..
PU
03/05COMPUGEN : to Present at the Cowen and Company 39th Annual Health Care Conferenc..
PR
01/22COMPUGEN : Announces Publication of Two Peer-Reviewed Papers Demonstrating the R..
PU
More news
Analyst Recommendations on COMPUGEN LTD.
More recommendations
Sector news : Biotechnology & Medical Research - NEC
06/19PFIZER : Fitch Puts Pfizer on Watch Negative, Notes Leverage Increase
DJ
06/19GILEAD SCIENCES : Sets Collaboration With Nurix Therapeutics
DJ
06/18WHAT'S NEWS : Business & Finance -- WSJ
DJ
06/18PFIZER : Expands Cancer-Treatment Lineup
DJ
06/17ARRAY BIOPHARMA : Pfizer makes $10.6 billion cancer bet in cash deal for Array B..
RE
More sector news : Biotechnology & Medical Research - NEC
Chart COMPUGEN LTD.
Duration : Period :
Compugen Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
EPS Revisions
Managers
NameTitle
Anat Cohen-Dayag President, Chief Executive Officer & Director
Paul Jai Sekhri Chairman
Ari Krashin Chief Operating & Financial Officer
Zurit Levine Vice President-Research & Discovery
Henry Adewoye Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
COMPUGEN LTD.63.06%168
IQVIA HOLDINGS INC32.77%26 223
LONZA GROUP31.41%24 012
CELLTRION, INC.--.--%20 953
INCYTE CORPORATION33.46%17 061
EXACT SCIENCES CORPORATION83.36%13 037